155 related articles for article (PubMed ID: 37593582)
1. Synthesis and anticancer evaluation of acetylated-lysine conjugated gemcitabine prodrugs.
Wang M; Qu K; Zhao P; Yin X; Meng Y; Herdewijn P; Liu C; Zhang L; Xia X
RSC Med Chem; 2023 Aug; 14(8):1572-1580. PubMed ID: 37593582
[TBL] [Abstract][Full Text] [Related]
2. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
[TBL] [Abstract][Full Text] [Related]
3. Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
Tsume Y; Drelich AJ; Smith DE; Amidon GL
Molecules; 2017 Aug; 22(8):. PubMed ID: 28796151
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360
[TBL] [Abstract][Full Text] [Related]
5. The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.
Tsume Y; Incecayir T; Song X; Hilfinger JM; Amidon GL
Eur J Pharm Biopharm; 2014 Apr; 86(3):514-23. PubMed ID: 24361461
[TBL] [Abstract][Full Text] [Related]
6. Development of bioactive gemcitabine-D-Lys
Sayyad N; Vrettos EI; Karampelas T; Chatzigiannis CM; Spyridaki K; Liapakis G; Tamvakopoulos C; Tzakos AG
Eur J Med Chem; 2019 Mar; 166():256-266. PubMed ID: 30716713
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
8. The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.
Tsume Y; Borras Bermejo B; Amidon GL
Pharmaceuticals (Basel); 2014 Jan; 7(2):169-91. PubMed ID: 24473270
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
Stephenson AA; Cao S; Taggart DJ; Vyavahare VP; Suo Z
Eur J Med Chem; 2021 Mar; 213():113135. PubMed ID: 33454548
[TBL] [Abstract][Full Text] [Related]
10. Stereocomplex Prodrugs of Oligo(lactic acid)
Tam YT; Huang C; Poellmann M; Kwon GS
ACS Nano; 2018 Jul; 12(7):7406-7414. PubMed ID: 29957934
[TBL] [Abstract][Full Text] [Related]
11. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.
Zhang L; Qi K; Xu J; Xing Y; Wang X; Tong L; He Z; Xu W; Li X; Jiang Y
J Med Chem; 2023 Mar; 66(6):4150-4166. PubMed ID: 36867101
[TBL] [Abstract][Full Text] [Related]
13. Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.
Zhong H; Mu J; Du Y; Xu Z; Xu Y; Yu N; Zhang S; Guo S
Biomacromolecules; 2020 Feb; 21(2):803-814. PubMed ID: 31995366
[TBL] [Abstract][Full Text] [Related]
14. Small Molecular Gemcitabine Prodrugs for Cancer Therapy.
Miao H; Chen X; Luan Y
Curr Med Chem; 2020; 27(33):5562-5582. PubMed ID: 31419928
[TBL] [Abstract][Full Text] [Related]
15. Novel developments in the use of antimetabolites.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):358-74. PubMed ID: 24940694
[TBL] [Abstract][Full Text] [Related]
16. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.
Vrettos EI; Karampelas T; Sayyad N; Kougioumtzi A; Syed N; Crook T; Murphy C; Tamvakopoulos C; Tzakos AG
Eur J Med Chem; 2021 Feb; 211():113018. PubMed ID: 33223264
[TBL] [Abstract][Full Text] [Related]
17. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.
Guo B; Wei J; Wang J; Sun Y; Yuan J; Zhong Z; Meng F
Acta Biomater; 2022 Jun; 145():200-209. PubMed ID: 35430336
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
[TBL] [Abstract][Full Text] [Related]
19. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.
Zhao C; Xue X; Li G; Sun C; Sun C; Qu X; Li W
Chem Biol Drug Des; 2012 Sep; 80(3):479-88. PubMed ID: 22642666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
